BioPharma Dive January 14, 2025
Executives at Amgen made the case for MariTide’s differentiation, while Merck’s CEO contended that Keytruda’s coming loss of exclusivity can be managed.
For any hopes the dealmaking that started the J.P. Morgan Healthcare Conference would give the overall biotechnology sector a running start to 2025, Eli Lilly deflated them Tuesday.
The company, which rose to new heights on the success of its medicines for weight loss and diabetes, revealed revenue numbers that for the second time in a row fell short of investor expectations. Lilly shares fell 7% and dragged with them the stocks of several other obesity drug developers. A biotech stock index slid by almost 3%.
Amgen is one of those would-be competitors and, at the...
Today's Sponsors
Today's Sponsor